85514-52-9

Usage

Uses

Used in Pharmaceutical and Chemical Industries:
(4-Benzyloxybutyl)triphenylphosphonium bromide is used as a phase transfer catalyst for improving the efficiency of certain reactions. Its ability to facilitate the movement of reactants between phases is particularly beneficial in the synthesis of complex organic molecules and pharmaceutical compounds.
Used as a Source of Bromine:
In certain reactions, the bromide anion in (4-Benzyloxybutyl)triphenylphosphonium bromide provides a source of bromine, which can be utilized for specific chemical processes that require the presence of bromide ions. This dual functionality makes it a versatile compound in various chemical applications.

Upstream product

• 60789-54-0 4-bromobutyl benzyl ether 
• 603-35-0 triphenylphosphine 

Downstream Products

• 139518-33-5 4-(benzyloxy)-1-phenylbutan-1-ol 
• 1365993-61-8 (2R,4S,5R,Z)-1-tert-butoxycarbonyl-2-(6-benzyloxyhex-2-enyl)-4,5-epoxypiperidine 
• 1628061-86-8 C₂₃H₃₂O₆ 

Relevant academic research and scientific papers

A new strategy for the stereoselective synthesis of 2,2′-bipyrrolidines

A new strategy for the stereoselective synthesis of the 2,2′-bipyrrolidine scaffold is presented using a metathesis reaction followed by asymmetric dihydroxylation for the introduction of the stereogenic elements. This straightforward high-yielding process is suitable for application to the synthesis of additional heterocycles.

Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors

This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.